Advances in AIDS Chemotherapy: The Asymmetric Synthesis of CRIXIVAN®
The discovery and development of an efficient, practical asymmetric synthesis of the HIV Protease inhibitor CRIXIVAN® is described. Particular emphasis is placed on the selective installation of each of the five stereogenic centers as well as design strategies associated with the preparation of a complex pharmaceutical agent needed in multiton quantities.
How to Cite
Copyright (c) 1997 Swiss Chemical Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.